Qiaoyun Tan

Chinese Academy Of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory Of Clinical Study On Anticancer Molecular Targeted Drugs
Beijing, 100021, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 16 publications

Longitudinal plasma proteomic analysis identifies biomarkers and combinational targets for anti-PD1-resistant cancer patients.

Longitudinal plasma proteomic analysis identifies biomarkers and combinational targets for anti-PD1-resistant cancer patients.

Journal: Cancer immunology, immunotherapy : CII

Published: November 21, 2023

High-Throughput Antigen Microarray Identifies Longitudinal Prognostic Autoantibody for Chemoimmunotherapy in Advanced Non-Small Cell Lung Cancer.

High-Throughput Antigen Microarray Identifies Longitudinal Prognostic Autoantibody for Chemoimmunotherapy in Advanced Non-Small Cell Lung Cancer.

Journal: Molecular & cellular proteomics : MCP

Published: August 11, 2023

Identification of novel prognostic autoantibodies in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone via a high-throughput antigen microarray.

Identification of novel prognostic autoantibodies in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone via a high-throughput antigen microarray.

Journal: Cancer

Published: July 03, 2023

Proteomics Identifies Circulating TIMP-1 as a Prognostic Biomarker for Diffuse Large B-Cell Lymphoma.

Proteomics Identifies Circulating TIMP-1 as a Prognostic Biomarker for Diffuse Large B-Cell Lymphoma.

Journal: Molecular & cellular proteomics : MCP

Published: January 28, 2023

Identification of novel serological autoantibodies in Chinese prostate cancer patients using high-throughput protein arrays.

Identification of novel serological autoantibodies in Chinese prostate cancer patients using high-throughput protein arrays.

Journal: Cancer immunology, immunotherapy : CII

Published: November 21, 2021

High-throughput and multi-phases identification of autoantibodies in diagnosing early-stage breast cancer and subtypes.

High-throughput and multi-phases identification of autoantibodies in diagnosing early-stage breast cancer and subtypes.

Journal: Cancer science

Published: July 07, 2021

Development and validation of a UPLC-MS/MS method to quantitate anti-PD1 monoclonal antibody (Toripalimab), and comparison with electrochemiluminescence immunoassay.

Development and validation of a UPLC-MS/MS method to quantitate anti-PD1 monoclonal antibody (Toripalimab), and comparison with electrochemiluminescence immunoassay.

Journal: Journal of pharmaceutical and biomedical analysis

Published: June 01, 2021

Anti-PD1/PDL1 IgG subclass distribution in ten cancer types and anti-PD1 IgG4 as biomarker for the long time survival in NSCLC with anti-PD1 therapy.

Anti-PD1/PDL1 IgG subclass distribution in ten cancer types and anti-PD1 IgG4 as biomarker for the long time survival in NSCLC with anti-PD1 therapy.

Journal: Cancer immunology, immunotherapy : CII

Published: May 18, 2021

Cytokines screening identifies MIG (CXCL9) for postoperative recurrence prediction in operated non-small cell lung cancer patients.

Cytokines screening identifies MIG (CXCL9) for postoperative recurrence prediction in operated non-small cell lung cancer patients.

Journal: Cytokine

Published: April 12, 2021

SLF1 polymorphism predicts response to oxaliplatin-based adjuvant chemotherapy in patients with colon cancer.

SLF1 polymorphism predicts response to oxaliplatin-based adjuvant chemotherapy in patients with colon cancer.

Journal: American journal of cancer research

Published: October 11, 2020

Autoantibody profiling identifies predictive biomarkers of response to anti-PD1 therapy in cancer patients.

Autoantibody profiling identifies predictive biomarkers of response to anti-PD1 therapy in cancer patients.

Journal: Theranostics

Published: March 09, 2020

Tracking longitudinal genetic changes of circulating tumor DNA (ctDNA) in advanced Lung adenocarcinoma treated with chemotherapy.

Tracking longitudinal genetic changes of circulating tumor DNA (ctDNA) in advanced Lung adenocarcinoma treated with chemotherapy.

Journal: Journal of translational medicine

Published: July 07, 2019

Showing 1-12 of 16

Last Updated: 09/26/2026